Medicaid Home & Community-Based Services: People Served and Spending During COVID-19 March 4, 2022 Issue Brief This issue brief presents FY 2020 state-level data on the number of people receiving Medicaid HCBS and HCBS spending. This is the latest data available, and the first since the onset of the COVID-19 pandemic. The data were collected in KFF’s 19th survey of state officials administering Medicaid HCBS programs in all 50 states and DC. A related brief presents the latest data and highlights themes in key state policy choices about optional HCBS.
Feb. 23 Web Event: The Gift of Experience vs. the Stress of Isolation: Older People Share How They’ve Made It Through the Pandemic February 23, 2022 Event Older adults have suffered more illness and death from covid-19 than any other group. How are they faring as the pandemic enters its third year? KFF’s Kaiser Health News (KHN) and The John A. Hartford Foundation explored that question in depth in a 90-minute interactive web event on Feb. 23,…
Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending January 27, 2022 News Release Twenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis. The 20 drugs include 18 drugs available to beneficiaries…
Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act January 27, 2022 Issue Brief The Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.
Why Medicare’s Aduhelm Coverage Decision Could Increase Pressure on Officials to Roll Back the Record Part B Premium Increase for 2022 January 14, 2022 News Release In a new Policy Watch, KFF experts explain why Medicare’s preliminary decision to cover a new Alzheimer’s drug only for a limited group of beneficiaries is likely to intensify pressure on officials to reconsider the increase in the Medicare Part B premium for 2022. Earlier this week, CMS issued a…
Monthly Part B Premiums and Annual Percentage Increases January 12, 2022 Slide The $21.60 increase in 2022 is the largest in dollar terms since the start of the program, even though premiums have risen faster in percentage terms on three other occasions in the last 20 years
Explaining the Prescription Drug Provisions in the Build Back Better Act November 23, 2021 Issue Brief The Build Back Better Act includes several provisions that would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government and private payers. This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation.
COVID-19 Outbreaks in Long-Term Care Facilities Were Most Severe in the Early Months of the Pandemic, but Data Show Cases and Deaths in Such Facilities May Be On the Rise Again September 1, 2020 News Release The rate of new COVID-19 cases and deaths in long-term care facilities declined markedly in May and June after the novel coronavirus swept through nursing homes in April, but recent data show the incidence may be on the rise again, according to a new KFF analysis. A second new analysis…
Overlooked and Undercounted: The Growing Impact of COVID-19 on Assisted Living Facilities September 1, 2020 Issue Brief This analysis examines the impact of COVID-19 on assisted living facilities, including changes in cases and deaths between June and August 2020, using state-reported data on COVID-19. The analysis finds a significant increase in COVID-19 cases and deaths among residents and staff in assisted living facilities over this two-month period. Due to the incomplete nature of state reporting, these numbers are an undercount.
State Actions to Sustain Medicaid Long-Term Services and Supports During COVID-19 August 26, 2020 Issue Brief As the COVID-19 pandemic continues, states have taken a number of Medicaid policy actions to address the impact on seniors and people with disabilities, many of whom rely on long-term services and supports (LTSS) to meet daily needs and are at increased risk of adverse health outcomes if infected with coronavirus.